{"id":691031,"date":"2022-10-03T07:24:53","date_gmt":"2022-10-03T11:24:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/"},"modified":"2022-10-03T07:24:53","modified_gmt":"2022-10-03T11:24:53","slug":"voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","title":{"rendered":"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Oct.  03, 2022  (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc.\u00a0(Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the upcoming 29<sup>th<\/sup> Annual Congress of the European Society of Gene &amp; Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh, Scotland.<\/p>\n<p>\n        <strong>Poster Presentation Details:<\/strong>\n      <\/p>\n<p>\n        <strong>Presentation Title:<\/strong> Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with\u00a0Enhanced Brain Tropism in Non-Human Primates and Mice<br \/><strong>Poster Number:<\/strong> P024<br \/><strong>Presenting Author:<\/strong> Brett Hoffman, Ph.D., Senior Scientist, Capsid Discovery<\/p>\n<p>\n        <strong>Presentation Title:<\/strong> Dose-Response Evaluation of 9P801, an Engineered AAV Capsid with High BBB Penetration and CNS Transduction in Non-Human Primates<br \/><strong>Poster Number:<\/strong> P015<br \/><strong>Presenting Author:<\/strong> Mathieu Nonnenmacher, Ph.D., Vice President, Capsid Discovery<\/p>\n<p>\n        <strong>Presentation Title:<\/strong> Evaluation of an Early, Late, Very Late Expressed Rep in a Recombinant Baculovirus to Produce a More Potent AAV-based Gene Therapeutic in Insect Cells<br \/><strong>Poster Number:<\/strong> P065<br \/><strong>Presenting Author:<\/strong> Jeffrey Slack, Ph.D., Principal Scientist, Cell Culture Development<\/p>\n<p>\n        <strong>About\u00a0Voyager Therapeutics<\/strong><br \/>\n        <br \/>Voyager Therapeutics\u00a0(Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Company\u2019s TRACER discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U7ijTM3PbOUHv2nv6suZnRmffj5zUSiH30Zs12IaqDNJF9UNoAPEp-bE3JSRxTlWm61foWor1-uaDRTmkrnMeg6AXVD55RMVTxK-8hNadAUjmEupNwiudi-DjnbtPkK5SQvH2sxeIPaBkOlhzs0I64m_aTiznO8DRAcCRSV5sydE9n2Vd12iGn8BC5fQawO6EtG9ImLE5_FBsU8IIiwNbkWga4db4zE8o5aYDySG5uyRaf_In_qc522VA6FxasTTDDsxYayQBxPrxxWwzvC3JDbzrqYBq_ijS72LiKI3NCAx-GDTPHTvf5i4rxDHEC21ImFpOECZSmFw4LP-4Ggri3riklw4ACpRJNOnG8KFFbeNyyulwidsd5BWLHKGP75hjf46X2PiBdKMRwh9sWbllQ5xkhZDH_uAuLCdbEA_3XzjhQTQz49CvJ5fm72fvJDc-tzygPkqzrD8SFUlmxDtwx3iRF6AIC389T3joFlLZyUghaTBPTOAW5UU7TaOCrdDRmj3JYHdCVfDq3C7I3lZIg==\" rel=\"nofollow noopener\" target=\"_blank\">voyagertherapeutics.com<\/a> \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S63af4r8wvv2uY10uk3Rnb0AX_VVALPbYSyJYptDKcS2X2J3DJu1IHnIAotPuvpzbw2EO24ChTp3QlqL3d7Z-JoxcfeIn-r5EppAxtdvipoRMSGHgKderbrVqq-5frVHX-PHTxlnev4kd_ii_LhvccRUDOejv_D-_23VvZzTrxvV8PCnb0gCAoVN9hNAL06Ch8fGvxCyF5LC5bRhUFCHwFyPI_T2-WvoQh9gf5TnaqSwiuADnsyKMjT1E69M2fmyH8Cm4Bn4C9QOO9gICemBzeaFJH3FWhNYrECI5TN9VLwwMKUywsj9fOHjn5XO_0Af0uYK652iFXXT0mMl-ClKelEo92aLqvWgpobLbmAknCbJhA5eWoatw-VVwANyooXKlAj4l6G5bBMo8fFqi6OBnvZmFbfperibschXS-QQRq6s7koVLsMe2DDIxxw2rgZeTyTggw6xAdh7tbxGDU_RQVhVkvofgTYYxhjfykfvok7a8fq2ydTnr0QeSVD0jx-y8nMs7RDgofJzac1Bi3mRsCEnPqgVWlzk5uBarpxe4MUh4qvl9XJpXcYwke0z5PSI\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>\u00a0 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nQGEs-2R7L5Zg6QVCBR4OYLnzL13aO4q1fYAZfT0QdGeclzsnkM5xpwTV4VVvrPWZQhyPwaJS0HhH9lLclwTlw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a><\/p>\n<p>Voyager Therapeutics<sup>\u00ae<\/sup> is a registered trademark, and TRACER\u2122 is a trademark, of\u00a0Voyager Therapeutics, Inc.\u00a0<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>Investors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5uPcvWblHlXleoElJXQBXPQMIL95JUSnb7NklyfAY5hLrLRi_Qq0QeeruQjdYUguY_G9eF65SJm5wMQodvaowzPXBnf9I291TmVI1n_UUag=\" rel=\"nofollow noopener\" target=\"_blank\">Investors@vygr.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Peg Rusconi<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b9DFGoSNc1OLwY-NQVFPp7uIKWun36S9TyA4WkxTkX-GPBoIsxhja01mQO3Wrdmrbx0qpDKCHHHMm99uYqm1mz3iErYHy_jk-N_4i27NFf-WKRQkNkJ2OJvOrQJ1JenS\" rel=\"nofollow noopener\" target=\"_blank\">prusconi@vergescientific.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDNmNTA5OGQtMDQ0NS00MDgyLTgyOTktMjUyYTc3MTVkNjcyLTEwMzA0MTM=\/tiny\/Voyager-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc.\u00a0(Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the upcoming 29th Annual Congress of the European Society of Gene &amp; Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh, Scotland. Poster Presentation Details: Presentation Title: Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with\u00a0Enhanced Brain Tropism in Non-Human Primates and MicePoster Number: P024Presenting Author: Brett Hoffman, Ph.D., Senior Scientist, Capsid Discovery Presentation Title: Dose-Response Evaluation of 9P801, an Engineered AAV Capsid with High BBB Penetration and CNS Transduction in Non-Human PrimatesPoster Number: P015Presenting Author: Mathieu Nonnenmacher, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-691031","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc.\u00a0(Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the upcoming 29th Annual Congress of the European Society of Gene &amp; Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh, Scotland. Poster Presentation Details: Presentation Title: Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with\u00a0Enhanced Brain Tropism in Non-Human Primates and MicePoster Number: P024Presenting Author: Brett Hoffman, Ph.D., Senior Scientist, Capsid Discovery Presentation Title: Dose-Response Evaluation of 9P801, an Engineered AAV Capsid with High BBB Penetration and CNS Transduction in Non-Human PrimatesPoster Number: P015Presenting Author: Mathieu Nonnenmacher, &hellip; Continue reading &quot;Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-03T11:24:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy\",\"datePublished\":\"2022-10-03T11:24:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\"},\"wordCount\":288,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\",\"name\":\"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=\",\"datePublished\":\"2022-10-03T11:24:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) &#8212; Voyager Therapeutics, Inc.\u00a0(Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that it will present three posters at the upcoming 29th Annual Congress of the European Society of Gene &amp; Cell Therapy (ESGCT), taking place October 11-14, 2022, in Edinburgh, Scotland. Poster Presentation Details: Presentation Title: Identification of a Cell Surface Receptor Utilized by an Engineered BBB-Penetrant Capsid Family with\u00a0Enhanced Brain Tropism in Non-Human Primates and MicePoster Number: P024Presenting Author: Brett Hoffman, Ph.D., Senior Scientist, Capsid Discovery Presentation Title: Dose-Response Evaluation of 9P801, an Engineered AAV Capsid with High BBB Penetration and CNS Transduction in Non-Human PrimatesPoster Number: P015Presenting Author: Mathieu Nonnenmacher, &hellip; Continue reading \"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-03T11:24:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy","datePublished":"2022-10-03T11:24:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/"},"wordCount":288,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/","name":"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=","datePublished":"2022-10-03T11:24:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzA5NiM1MTgyMzIyIzIwMTg4NDA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/voyager-therapeutics-announces-data-presentations-at-the-29th-annual-congress-of-the-european-society-of-gene-cell-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene &amp; Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=691031"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691031\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=691031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=691031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=691031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}